Roivant Sciences Ltd. is a pharmaceutical company that builds subsidiary biotech and health technology companies.

Roivant's initial strategy of in-licensing late-stage drug candidates through subsidiaries was later expanded to develop earlier stage drug candidates and other healthcare technologies through those same subsidiaries.

Roivant was founded in 2014 by Vivek Ramaswamy. The company is headquartered in Basel, Basel-Stadt, Switzerland with additional offices in New York, New York and Durham, North Carolina.


Roivant’s drug discovery capabilities include the leading computational physics-based platform for in silico drug design and optimization as well as machine learning-based models for protein degradation.


Roivant's integration of computational and experimental engines enables the rapid design of molecules with high precision and fidelity to address challenging targets for diseases with high unmet need.


Roivant is also a leader in computational drug discovery through its combination of computational physics and machine learning-based platforms for the in silico design of small molecules.


Roivant is backed by SoftBank Vision Fund, Viking Global Investors, RTW Investments, Novaquest Capital Management and many others. The company raised $200M in a Private Equity round on Nov 13, 2018. This brings Roivant's total funding to $1.9B to-date. The company was valued at $7B from a financing raised in Nov 2018. Roivant struck a SPAC deal valuing the company at $7.3B in May 2021.



  • Year founded: 2014
  • Funding Info: $1.9B over 5 Rounds (Latest Funding Type: Private Equity)
  • Yearly Revenue: NA
  • Employee Size: 201-500
  • Business Valuation: Valued at a $7B as of Nov 13, 2018
  • City/Town: Basel
  • State: Basel-Stadt
  • Country: Switzerland
Related businesses